Profile data is unavailable for this security.
About the company
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
- Revenue in INR (TTM)81.85bn
- Net income in INR16.74bn
- Incorporated1990
- Employees17.50k
- LocationDivi's Laboratories Ltd1-72/23(P)/Divis/303, Divi Towers, Cyber Hills, Gachibowli,HYDERABAD 500032IndiaIND
- Phone+91 4 023786300
- Fax+91 4 023786460
- Websitehttps://www.divislabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd | 127.32bn | 20.54bn | 743.32bn | 17.28k | 36.18 | -- | 31.22 | 5.84 | 171.81 | 171.81 | 1,064.87 | -- | -- | -- | -- | 7,369,150.00 | -- | 11.88 | -- | 17.50 | 62.21 | 59.26 | 16.29 | 13.94 | -- | 9.12 | -- | 29.82 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 297.18bn | 35.21bn | 901.67bn | 8.80k | 25.82 | -- | 17.72 | 3.03 | 60.12 | 60.12 | 507.19 | -- | -- | -- | -- | 33,782,390.00 | -- | 9.24 | -- | 13.43 | 57.87 | 53.30 | 11.84 | 12.72 | -- | 13.17 | -- | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Mankind Pharma Ltd | 106.50bn | 19.63bn | 983.76bn | 19.54k | 50.20 | -- | 40.83 | 9.24 | 48.91 | 48.91 | 265.43 | -- | -- | -- | -- | 5,450,142.00 | -- | -- | -- | -- | 69.93 | -- | 18.69 | -- | -- | -- | -- | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Lupin Ltd | 207.97bn | 22.64bn | 1.04tn | 20.79k | 45.86 | -- | 31.42 | 4.98 | 49.50 | 49.50 | 454.84 | -- | -- | -- | -- | 10,003,890.00 | -- | 1.43 | -- | 2.22 | 67.58 | 58.52 | 11.00 | 2.04 | -- | 9.67 | -- | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Dr Reddy's Laboratories Ltd | 289.49bn | 55.65bn | 1.10tn | 26.34k | 19.87 | -- | 15.64 | 3.82 | 333.72 | 333.72 | 1,735.89 | -- | -- | -- | -- | 10,989,370.00 | -- | 11.37 | -- | 16.02 | 70.80 | 65.86 | 19.22 | 14.63 | -- | 36.60 | -- | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Zydus Lifesciences Ltd | 206.15bn | 41.69bn | 1.12tn | 26.24k | 26.92 | -- | 22.44 | 5.42 | 41.28 | 41.51 | 204.01 | -- | -- | -- | -- | 7,856,441.00 | -- | 9.05 | -- | 14.01 | 70.22 | 61.15 | 20.29 | 14.33 | -- | -- | -- | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Torrent Pharmaceuticals Ltd | 109.96bn | 17.35bn | 1.17tn | 14.92k | 67.35 | -- | 46.07 | 10.63 | 51.27 | 51.27 | 324.85 | -- | -- | -- | -- | 7,371,843.00 | -- | 8.34 | -- | 13.03 | 75.17 | 71.78 | 15.78 | 13.18 | -- | 8.19 | -- | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 261.39bn | 43.03bn | 1.35tn | 27.76k | 31.38 | -- | 25.03 | 5.16 | 53.27 | 53.27 | 323.59 | -- | -- | -- | -- | 9,414,760.00 | -- | 10.09 | -- | 12.40 | 66.43 | 58.63 | 16.58 | 12.66 | -- | 59.65 | -- | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Divi's Laboratories Ltd | 81.85bn | 16.74bn | 1.45tn | 17.50k | 86.47 | -- | 70.40 | 17.68 | 63.05 | 63.05 | 308.33 | -- | -- | -- | -- | 4,677,143.00 | -- | 16.55 | -- | 18.22 | 59.76 | 56.24 | 20.45 | 26.38 | -- | -- | -- | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Holder | Shares | % Held |
|---|---|---|
| SBI Funds Management Ltd.as of 31 Aug 2024 | 17.53m | 6.60% |
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Mar 2024 | 16.17m | 6.09% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 4.80m | 1.81% |
| Axis Asset Management Co. Ltd.as of 31 Aug 2024 | 3.83m | 1.44% |
| Norges Bank Investment Managementas of 31 Mar 2024 | 3.27m | 1.23% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 3.26m | 1.23% |
| Wasatch Advisors LPas of 30 Jun 2024 | 3.09m | 1.16% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 05 Sep 2024 | 3.06m | 1.15% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Aug 2024 | 1.72m | 0.65% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 2024 | 1.48m | 0.56% |
